Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirukumab monotherapy in Japanese patients with active rheumatoid arthritis
NCT01689532Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2012
- Primary completion
- Mar 2015
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sirukumab in rheumatoid arthritis (RA), sponsored by Janssen Pharmaceutical. Primary endpoint: Treatment Emergent Adverse Events at 68 weeks. Started Nov 2012; status: completed.
02
Drugs
sirukumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01689532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01689532.